Myopericarditis After mRNA COVID-19 Vaccine in a Patient With Recent History of COVID-19

Eiman Elhouderi 1, Eman Elsawalhy 1, Mohamed Kabbani 1

1. Internal Medicine, Beaumont Health, Dearborn, USA

Corresponding author: Eiman Elhouderi, eimanna87@gmail.com

Abstract
Myopericarditis has been identified as a potential adverse event of several vaccines in the medical literature. Here we present a case of a 30-year-old male who had myopericarditis a week after receiving the second booster dose of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine. The patient’s clinical course was not severe and had a full recovery after a week of treatment.

Introduction
Myopericarditis is inflammation of the pericardial membrane that is associated with a mild degree of myocardial inflammation manifesting by elevation in cardiac enzymes (troponin). Recently, multiple cases of myopericarditis have been reported one week after receiving the second booster dose of mRNA coronavirus disease 2019 (COVID-19) vaccination as Pfizer-BioNTech and Moderna [1]. In the past, the same adverse event occurred after administration of vaccinations against other viruses such as smallpox virus. However, the exact mechanism is unclear [2]. Myopericarditis can be managed conservatively and most of the patients have excellent outcomes. Our patient had complete recovery after one week of management.

Case Presentation
A 30-year-old African American male with a history of COVID-19 infection two months ago presented to the hospital after one week of receiving a second dose of the Pfizer-BioNTech COVID-19 vaccine. He presented with midsternal chest pain, fever, chills, and shortness of breath. The vital signs on arrival included a blood pressure of 159/101, heart rate of 90 beats/minute, respiratory rate of 18 breaths/minute, and oxygen saturation of 98%. The physical exam was normal. The lab report was significant for elevated troponin of 2.9 ng/ml that continued trending up to 20.43 ng/ml and elevated inflammatory markers including C-reactive protein of 115.4 mg/l and erythrocyte sedimentation rate of 26 mm/hr. The COVID-19 polymerase chain reaction (PCR) test was negative. The chest X-ray was normal. EKG showed diffuse J-point elevation on inferolateral leads that progressed to 4-5 mm in the anterior, lateral, and inferior leads on the repeat EKG (Figure 1). Echocardiography showed normal left ventricular systolic function and no segmental wall motion abnormalities.

FIGURE 1: EKG showing ST-elevation in the inferior and anterolateral leads

VIDEO 1: Echocardiography, two chambers view.
Given the up-trending troponin level and the progressive EKG changes, coronary angiography was done to rule out ischemic heart disease and revealed normal coronary arteries.

Given the recent history of vaccination and elevated inflammatory markers, the diagnosis was presumed to be myopericarditis related to the COVID-19 vaccine. The patient was managed with steroid and non-steroidal anti-inflammatory medications. He was then discharged in stable clinical condition. Follow-up in one week confirmed complete symptomatic recovery.

**Discussion**

Myopericarditis is caused by different factors including infection, vaccines, drugs, autoimmune diseases, and radiation. Viral infection is the most common cause of myopericarditis. Myopericarditis is shown to be caused by different types of vaccines with the smallpox vaccine being the most common one [3,4]. Diagnosis of myopericarditis requires both fulfilling the criteria for pericarditis and the presence of finding of myocardial involvement [3,5]. Criteria for diagnosis of pericarditis include the presence of at least two of the following four criteria; typical chest pain, pericardial friction rub, ST-segment elevation or pericardial effusion. The clues for myocardial inflammation include focal or generalized ST elevation on EKG, the elevation of cardiac biomarkers or echocardiographic evidence of focal or global ventricular dysfunction with the exclusion of other causes for decreased ventricular function such as acute coronary syndrome. The diagnosis can be confirmed by the evidence of myocarditis on cardiac magnetic resonance imaging in the presence of elevated troponin or endomyocardial biopsy. In the appropriate clinical setting, the elevation of inflammatory markers such as C-reactive protein or erythrocyte sedimentation rate provides supportive evidence for the diagnosis of myopericarditis [5]. Myopericarditis can be treated as acute pericarditis with the use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroid [3].

Interestingly, this case demonstrated that recent history (less than six months) of previous COVID-19 might be associated with an increased risk of COVID-19 vaccine myopericarditis. Fortunately, this case showed that elevated troponin and EKG abnormalities might not be associated with left ventricular dysfunction or poor outcome.

COVID-19 infection is associated with myocarditis and pericarditis. A preprint from a population-based analysis showed that the incidence of myocarditis in young males is as high as 450 per million. However, observation studies from hospitalized patients showed a higher incidence than that [6]. The mechanism of COVID-19 induced myopericarditis is not known but is hypothesized that it is a result of immunological response to the virus rather than direct viral infection of cardiac myocytes [7,8].

As of March 3, 2022, the Center for Disease Control (CDC) has verified 1,337 reports of myocarditis or pericarditis associated with COVID-19 vaccines. The majority of cases have been reported after receiving the second dose of mRNA COVID-19 vaccines and in young males [9]. Myopericarditis has been also reported after the non-mRNA COVID-19 vaccine such as the AstraZeneca vaccine [10]. A case of a 50-year-old male who developed myopericarditis after the second dose of the Pfizer vaccine has been reported. The patient was tested negative for COVID-19 at the time of the presentation and he had very high Anti-spike IgG of more than 40,000 AU/ml [11]. A case series illustrated four cases of myocarditis that occurred 2-5 days after the second dose of mRNA COVID-19 vaccine have been published [12]. Both the case report and case series didn’t report if the patients have a history of prior COVID-19 infection. A literature review showed only one case report of myopericarditis after the first dose of the Pfizer vaccine in a patient with a confirmed recent prior history of COVID-19 [13].

Studies showed that self-reported previous COVID-19 is associated with 2.1 times higher risk of COVID-19 vaccine adverse events [14]. Moreover, the COVID-19 symptom study app illustrated that systemic side effects after the second dose of the Pfizer vaccine were higher in people with prior history of COVID-

2022 Elhouderi et al. Cureus 14(5): e25264. DOI 10.7759/cureus.25264
19 (38%) as compared to people with no history of prior COVID-19 (20%) [15]. In addition, studies showed that previous COVID-19 infection is associated with an increase in the peak level of Anti-spike IgG antibody after COVID-19 vaccines [16]. Since COVID-19 infection can be asymptomatic, especially in young people [17], it is difficult to confirm if patients who developed COVID-19 myopericarditis have prior COVID-19 infection or not. Our case report is the first case report to shed light on the possible association between recent prior COVID-19 infection and myopericarditis after the COVID-19 vaccine. Further studies are warranted to explore this association.

Conclusions

In summary, this case report showed that myopericarditis can be associated with the COVID-19 vaccine, particularly the mRNA vaccine. This adverse event occurs most commonly in young males. Previous COVID-19 infection might be associated with the increased risk of COVID-19-vaccine-related myopericarditis and further study is warranted to explore this association. This condition can be managed supportively and has a favorable outcome. Given the well-established COVID-19 infection mortality and morbidity, this potential rare adverse event should not lessen our confidence in the vaccine.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Husby A, Hansen JV, Fosbol E, et al.: SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021, 375:e068665. 10.1136/bmj-2021-068665
2. Halsej IS, Riddle JR, Atwood JE, et al.: Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA. 2003, 289:3283-9. 10.1001/jama.289.24.3283
3. Inazio M, Trinchero R: Myopericarditis: etiology, management, and prognosis. Int J Cardiol. 2008, 127:171-7. 10.1016/j.ijcard.2007.10.053
4. Su JR, McNeil MM, Welsh KJ, Marquez PL, Ng C, Yan M, Cano MV: Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. Vaccine. 2021, 39:839-45. 10.1016/j.vaccine.2020.12.046
5. Gluckman TJ, Bhave NM, Allen LA, et al.: 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022, 79:1717-56. 10.1016/j.jacc.2022.02.003
6. Singer ME, Taub IB, Kaehler DC: Risk of myocarditis from COVID-19 infection in people under age 20: a population-based analysis. medRxiv. 2022. 10.1101/2021.07.25.21260998
7. Mansuetto G, Niola M, Napoli C: Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?. Pathol Res Pract. 2020, 216:153086. 10.1016/j.prp.2020.153086
8. Sulemankhil I, Abdelrahman M, Negi SI: Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: a case report and literature review. Cardiovasc Revasc Med. 2022, S8117-25. 10.1016/j.carrev.2021.08.012
9. Misqdad NA, Nasser H, Alshehri A, Mourad AR: Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection and acute myocarditis: a case report and literature review. JAMA Cardiol. 2021, 6:e20979. 10.1001/jamacardio.2021.05.010
10. Farooq M, Mohamed Y, Zafar M, Dharmasena D, Rana UI, Kankam O: COVID-19 vaccine-induced pneumonitis, myositis and myopericarditis. Cureus. 2022, 14:e20978. 10.7759/cureus.20978
11. D’Angelo T, Cattafi A, Caretti ML, et al.: Myopericarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?. Can J Cardiol. 2021, 37:1665-7. 10.1016/j.cjca.2021.05.010
12. King WW, Petersen MR, Matar RM, Budweg JB, Cuervo Pardo L, Petersen JW: Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J. Plus. 2021, 8:10042. 10.1016/j.ahjplus.2021.100042
13. Patrignani A, Schicchi N, Ciacignoli F, Falchetti E, Ciampani N, Argulia G, Mariani A: Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep. 2021, 16:3521-5. 10.1016/j.rscr.2021.07.082
14. Beatty AL, Peyer SD, Butcher XE, et al.: Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021, 4:e2140564. 10.1001/jamanetworkopen.2021.40364
15. Menni C, Klauser K, May A, et al.: Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021, 21:939-49. 10.1016/s1473-3099(21)00224-3
16. Wei J, Pouwels KB, Stoesser N, et al.: Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022, 28:1072-82. 10.1038/s41591-022-01721-6
17. Ma Q, Liu J, Liu Q, et al.: Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw Open. 2021, 4:e2137257. 10.1001/jamanetworkopen.2021.37257